Trinity Biotech (NASDAQ:TRIB) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Trinity Biotech (NASDAQ:TRIB) in a research report sent to investors on Wednesday. The firm issued a buy rating on the stock.

Trinity Biotech Price Performance

NASDAQ:TRIB opened at $2.59 on Wednesday. The company has a market cap of $19.74 million, a price-to-earnings ratio of -0.93 and a beta of 1.16. Trinity Biotech has a 1 year low of $1.49 and a 1 year high of $5.50. The stock’s 50 day simple moving average is $1.91 and its two-hundred day simple moving average is $2.17.

Trinity Biotech (NASDAQ:TRIB) last announced its quarterly earnings results on Thursday, May 23rd. The company reported ($0.37) earnings per share for the quarter. As a group, analysts anticipate that Trinity Biotech will post -2.17 EPS for the current year.

Trinity Biotech Company Profile

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.